OncoMatch/Clinical Trials/NCT07205536
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Is NCT07205536 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mecapegfilgrastim and Oral or short-acting granulocyte-stimulating agents for myelosuppression.
Treatment: Mecapegfilgrastim · Oral or short-acting granulocyte-stimulating agents — This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.
Check if I qualifyEligibility summary
For patients with Esophageal Carcinoma, Non-Small Cell Lung Cancer or Small Cell Lung Cancer.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify